Key result
Roux-en-Y gastric bypass resulted in total remission of type 2 diabetes in 37.9% and hypertension in 43.7% of affected patients, alongside reduced medication use.
Why the study?
Although lifestyle changes can control obesity-related comorbidities, most patients struggle with glucose control, prompting evaluation of the effect of Roux-en-Y gastric bypass on diabetes and hypertension.
Does Roux-en-Y gastric bypass improve remission of type 2 diabetes and systemic arterial hypertension in obese patients?
Cohort (n=252)
Does Roux-en-Y gastric bypass improve remission of type 2 diabetes and systemic arterial hypertension in obese patients?
Roux-en-Y gastric bypass is associated with high rates of total remission of type 2 diabetes and systemic arterial hypertension, as well as a reduced medication burden.
Roux-en-Y bypass was associated with diabetes and hypertension remission in obese patients; leaves open confirmation in randomized trials.
INTRODUCTION: obesity has become a public health problem in Brazil and worldwide, due to its high prevalence. It is considered a risk factor for systemic arterial hypertension (SAH) and type 2 diabetes mellitus T2DM. Although lifestyle changes can control and even achieve complete T2DM remission, most patients have difficulty controlling blood glucose. Recent studies show that the Roux-en-Y gastric bypass (RYGB) is efficient for weight loss and control of T2DM and SAH in obese individuals. OBJECTIVE: to analyze the effect of the RYGB technique on the control and treatment of comorbidities related to obesity. METHOD: this is a retrospective cohort study, with information obtained from the review of medical records, with data collection in the pre and postoperative period of patients undergoing bariatric surgery. We selected those with T2DM and SAH for the study. RESULTS: 252 patients underwent RYGB in the service. Seventy-nine (31.3%) had T2DM and 64 had SAH associated with T2DM. Regarding T2DM and SAH, 37.9% and 43,7%, respectively, showed total remission of the disease after surgery. There was a reduction in the postoperative use of Metformin, insulin / Gliclazide, Propranolol, Losartan and Hydrochlorothiazide in 62%, 10.1%, 100%, 26.5% and 22.8% of patients, respectively. CONCLUSION: the RYGB technique is effective in the remission of T2DM and SAH. Even in cases where there was no total remission of the diseases, there was a significant drop in the use of medicines used for their treatment.
No takes yet. Share an insight, caveat, or question.
Marchetti et al. (2020) conducted a cohort in Obesity with Type 2 Diabetes Mellitus and Systemic Arterial Hypertension (n=252). Roux-en-Y gastric bypass (RYGB) vs. Preoperative baseline was evaluated on Total remission of T2DM and SAH. Roux-en-Y gastric bypass resulted in total remission of type 2 diabetes in 37.9% and hypertension in 43.7% of affected patients, alongside reduced medication use.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: